<DOC>
	<DOCNO>NCT00962663</DOCNO>
	<brief_summary>The purpose study ; determine pharmacodynamic ( PD ) effect ICA-105665 use intradermal ( ID ) capsaicin model healthy male subject , investigate effect ICA-105665 inflammatory hyperalgesia use ultraviolet B ( UV-B ) model healthy male subject .</brief_summary>
	<brief_title>Effects ICA-105665 Using Intradermal Capsaicin Ultraviolet B ( UV-B ) Models Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Capsaicin</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy male age 18 55 year ( inclusive ) . Body mass index ( BMI ) 18 30 kg/m2 . Nonsmokers smokers 5 cigarette equivalent per day . Must able abstain smoke residential period . Demonstration positive hyperalgesia define area hyperalgesia = 15 cm2 15 minute ID administration 100 µg capsaicin . Demonstration negative hyperalgesia define area hyperalgesia &lt; 5 cm2 15 minute ID administration capsaicin vehicle . Subject skin type compatible measure , without significant skin allergy , pigmentary disorder , active dermatological condition might interfere conduct study . Subject clinically significant illness 4 week screen . Use prescribed medication herbal supplement 7 day prior dose counter preparation , include multivitamin paracetamol , 48 h dosing . Subject significant history drug/solvent abuse ( within 2 year prior Day 1 ) , positive drug abuse test screening . Subject history alcohol abuse currently drink excess 28 unit per week ( male ) , positive breath alcohol test Screening visit Day 1 . Subject Heat pain tolerance threshold ( HPTT ) = 50°C screening . Subjects develop erythema high intensity UVB light use establish Minimum erythema dose ( MED ) . Known allergy intolerance capsaicin hot pepper . Subjects skin trauma , scar skin disorder tattoo forearm front thigh . Subject active chronic pain condition history chronic pain condition . Any condition might interfere absorption , distribution , metabolism , and/or excretion drug . Previous ingestion ICA105665 . Considering schedule undergo surgical procedure duration study . Prolonged QT/QTc interval ( repeatedly = 450 msec ) . Received agent know alter hepatic renal clearance ( e.g. , erythromycin , cimetidine , barbiturate , phenothiazine , clarithromycin , troleandomycin , ketoconazole , miconazole , fluconazole , itraconazole , etc . ) period 30 day prior Day 1 . History risk factor Torsades de Pointes ( family history long QT syndrome , heart failure , hypokalemia ) . Subject unable tolerate blindfold . Subject participate clinical study involve capsaicin within 1 year Screening visit . Subject history skin cancer . Subject clinically significant history anemia .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>